NO762586L - - Google Patents
Info
- Publication number
- NO762586L NO762586L NO762586A NO762586A NO762586L NO 762586 L NO762586 L NO 762586L NO 762586 A NO762586 A NO 762586A NO 762586 A NO762586 A NO 762586A NO 762586 L NO762586 L NO 762586L
- Authority
- NO
- Norway
- Prior art keywords
- precipitate
- methanol
- supernatant
- temperature
- iii
- Prior art date
Links
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 67
- 239000002244 precipitate Substances 0.000 claims description 40
- 239000007788 liquid Substances 0.000 claims description 20
- 239000006228 supernatant Substances 0.000 claims description 17
- 102000006395 Globulins Human genes 0.000 claims description 13
- 108010044091 Globulins Proteins 0.000 claims description 13
- 108010074605 gamma-Globulins Proteins 0.000 claims description 12
- 150000002632 lipids Chemical class 0.000 claims description 11
- 108010051456 Plasminogen Proteins 0.000 claims description 9
- 102000013566 Plasminogen Human genes 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 102000008946 Fibrinogen Human genes 0.000 claims description 6
- 108010049003 Fibrinogen Proteins 0.000 claims description 6
- 229940012952 fibrinogen Drugs 0.000 claims description 6
- 208000002672 hepatitis B Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 230000003053 immunization Effects 0.000 claims description 2
- 238000002649 immunization Methods 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 description 16
- 208000006454 hepatitis Diseases 0.000 description 12
- 231100000283 hepatitis Toxicity 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 238000005194 fractionation Methods 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 108010087504 Beta-Globulins Proteins 0.000 description 5
- 239000008351 acetate buffer Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000006734 Beta-Globulins Human genes 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 102100027378 Prothrombin Human genes 0.000 description 3
- 108010094028 Prothrombin Proteins 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000035931 haemagglutination Effects 0.000 description 3
- 229940036107 hepatitis b immunoglobulin Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229940039716 prothrombin Drugs 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 108010068307 Alpha-Globulins Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002572 Alpha-Globulins Human genes 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- -1 isoalutinins Proteins 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/804—Radioisotope, e.g. radioimmunoassay
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/82—Hepatitis associated antigens and antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
- Y10S530/831—Cohn fractions
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/599,619 US4021540A (en) | 1975-07-28 | 1975-07-28 | Preparation of a hepatitis B immune globulin and use thereof as a prophylactic material |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO762586L true NO762586L (es) | 1977-01-31 |
Family
ID=24400364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO762586A NO762586L (es) | 1975-07-28 | 1976-07-23 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4021540A (es) |
| JP (1) | JPS5215814A (es) |
| AU (1) | AU512235B2 (es) |
| BE (1) | BE844566A (es) |
| CA (1) | CA1069822A (es) |
| DE (1) | DE2633932A1 (es) |
| DK (1) | DK336776A (es) |
| ES (1) | ES450208A1 (es) |
| FR (1) | FR2319376A1 (es) |
| GB (1) | GB1548014A (es) |
| IL (1) | IL50134A (es) |
| IT (1) | IT1192145B (es) |
| NO (1) | NO762586L (es) |
| PH (1) | PH11597A (es) |
| PT (1) | PT65411B (es) |
| SE (1) | SE7608475L (es) |
| ZA (1) | ZA764509B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1064396A (en) * | 1975-02-18 | 1979-10-16 | Myer L. Coval | Fractional precipitation of gamma globulin with polyethylene glycol |
| US4164495A (en) * | 1976-04-06 | 1979-08-14 | Nordisk Insulinlaboratorium | Method of recovering immunoglobulin using a polyol and an alkanoic acid |
| DK139056B (da) * | 1976-04-06 | 1978-12-11 | Nordisk Insulinlab | Fremgangsmåde til udvinding af immunoglobulin, der er egnet til intravenøs indgivelse. |
| US4165370A (en) * | 1976-05-21 | 1979-08-21 | Coval M L | Injectable gamma globulin |
| US4174388A (en) * | 1977-02-14 | 1979-11-13 | Merck & Co., Inc. | Method for preparing hepatitis B immune globulin |
| JPS5822085B2 (ja) * | 1977-07-19 | 1983-05-06 | 株式会社ミドリ十字 | 静注用ガンマ・グロブリン製剤 |
| US4296027A (en) * | 1977-08-31 | 1981-10-20 | The Regents Of The University Of Minnesota | Pure intravenous human and animal gamma globulins |
| US6297355B1 (en) | 1978-12-22 | 2001-10-02 | Biogen, Inc. | Polypeptides displaying HBV antigenicity or hbv antigen specificity |
| US4346073A (en) * | 1980-04-11 | 1982-08-24 | The United States Of America As Represented By The Department Of Health And Human Services | Hepatitis B immune globulin used to inactivate hepatitis B virus in injectable biological products |
| AU8746582A (en) * | 1981-09-02 | 1983-03-10 | Biogen N.V. | Hepatitis b virus e type antigen |
| JPS5855432A (ja) * | 1981-09-29 | 1983-04-01 | Fujirebio Inc | 静脈注射用免疫グロブリンの製法 |
| US4482483A (en) * | 1983-04-06 | 1984-11-13 | Armour Pharmceutical Company | Composition of intravenous immune globulin |
| US4719290A (en) * | 1983-09-02 | 1988-01-12 | Armour Pharmaceutical Corporation | Composition of intravenous immune globulin |
| DE4115910A1 (de) * | 1991-05-15 | 1992-11-19 | Schweigle Bernhard Dipl Chem | Verfahren zur herstellung von nativem, intravenoes verabreichbarem, stabilisiertem immunglobulin |
| US6096872A (en) * | 1997-10-14 | 2000-08-01 | Ortho Diagnostic Systems, Inc. | Viral clearance process |
| AU784808B2 (en) * | 2001-04-02 | 2006-06-29 | Kedrion Melville Inc. | Prion and viral clearance process |
| AU2003241596B2 (en) * | 2002-05-23 | 2010-01-21 | Kedrion Melville Inc. | Capture, concentration and quantitation of abnormal prior protein from biological fluids using depth filtration |
| AU2005229674B2 (en) * | 2004-11-18 | 2010-11-04 | Kedrion Melville Inc. | Low concentration solvent/detergent process of immuneglobulin with pre-treatment |
| US9815886B2 (en) | 2014-10-28 | 2017-11-14 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
| US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1539016A (fr) * | 1966-06-03 | 1968-09-13 | Ortho Pharma Corp | Procédé de production de gobuline anti-rh |
-
1975
- 1975-07-28 US US05/599,619 patent/US4021540A/en not_active Expired - Lifetime
-
1976
- 1976-06-21 PH PH18590A patent/PH11597A/en unknown
- 1976-06-21 CA CA255,319A patent/CA1069822A/en not_active Expired
- 1976-06-23 GB GB26171/76A patent/GB1548014A/en not_active Expired
- 1976-06-28 AU AU15359/76A patent/AU512235B2/en not_active Expired
- 1976-07-23 NO NO762586A patent/NO762586L/no unknown
- 1976-07-26 DK DK336776A patent/DK336776A/da not_active Application Discontinuation
- 1976-07-26 IT IT50604/76A patent/IT1192145B/it active
- 1976-07-27 BE BE169283A patent/BE844566A/xx unknown
- 1976-07-27 IL IL50134A patent/IL50134A/xx unknown
- 1976-07-27 FR FR7622904A patent/FR2319376A1/fr active Granted
- 1976-07-27 JP JP51088755A patent/JPS5215814A/ja active Pending
- 1976-07-27 ZA ZA00764509A patent/ZA764509B/xx unknown
- 1976-07-27 ES ES450208A patent/ES450208A1/es not_active Expired
- 1976-07-27 SE SE7608475A patent/SE7608475L/xx unknown
- 1976-07-27 PT PT65411A patent/PT65411B/pt unknown
- 1976-07-28 DE DE19762633932 patent/DE2633932A1/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| FR2319376A1 (fr) | 1977-02-25 |
| US4021540A (en) | 1977-05-03 |
| ZA764509B (en) | 1978-03-29 |
| DK336776A (da) | 1977-01-29 |
| BE844566A (fr) | 1977-01-27 |
| IL50134A (en) | 1979-09-30 |
| ES450208A1 (es) | 1977-08-16 |
| IT1192145B (it) | 1988-03-31 |
| PT65411A (en) | 1976-08-01 |
| AU512235B2 (en) | 1980-10-02 |
| PH11597A (en) | 1978-03-31 |
| DE2633932A1 (de) | 1977-02-17 |
| SE7608475L (sv) | 1977-01-29 |
| IL50134A0 (en) | 1976-09-30 |
| PT65411B (en) | 1978-06-09 |
| AU1535976A (en) | 1978-01-05 |
| GB1548014A (en) | 1979-07-04 |
| CA1069822A (en) | 1980-01-15 |
| FR2319376B1 (es) | 1979-07-13 |
| JPS5215814A (en) | 1977-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO762586L (es) | ||
| Woodruff et al. | Effect of antilymphocytic antibody and antibody fragments on human lymphocytes in vitro | |
| Gürcan et al. | A review of the current use of rituximab in autoimmune diseases | |
| BIELORY et al. | Human serum sickness: a prospective analysis of 35 patients treated with equine anti-thymocyte globulin for bone marrow failure | |
| Fudenberg et al. | “Acquired Agammaglobulinemia” with Auto‐Immune Hemolytic Disease: Graft‐versus‐Host Reaction? | |
| US3869436A (en) | Method for fractionating plasma proteins using peg and ion-exchangers | |
| Weir | Liver autoantibodies in the rat | |
| Herbert et al. | The administration of adrenocorticotrophic hormone to normal human subjects. The effect of the leucocytes in the blood and on circulating antibody levels | |
| Frommhagen et al. | The role of aggregated γ-globulins in the anticomplementary activity of human and animal sera | |
| Henson et al. | Immunological induction of increased vascular permeability: I. A rabbit passive cutaneous anaphylactic reaction requiring complement, platelets, and neutrophils | |
| JP2926463B2 (ja) | 抗ｄ−免疫グロブリンｇの濃縮物の製造方法、それを含む製薬的調剤 | |
| Laurell et al. | Electrophoretic studies of the conversion products of serum β1C-globulin | |
| Stevens et al. | Studies on antibody synthesis initiated in vitro | |
| Neftel et al. | Effect of storage of penicillin-G solutions on sensitisation to penicillin-G after intravenous administration | |
| Carter | Rh hapten: its preparation, assay and nature | |
| Stark et al. | Sensitization to human lymphocyte antigens by corneal transplantation | |
| Julianelle et al. | Immunological Specificity of Carbohydrates Derived from Staphylococci. | |
| Robinson et al. | Plasmapheresis followed by intravenous immunoglobulin in presensitized patients awaiting thoracic organ transplantation | |
| CN107028982B (zh) | 人胎盘乙型肝炎特异免疫活性多肽 | |
| Gerber et al. | Attempts to transmit infectious mononucleosis to rhesus monkeys and marmosets and to isolate herpes-like virus | |
| Karthigasu et al. | The nature of the opsonins in adult hen serum and developing chick embryos to certain Gram‐negative bacteria | |
| Nakamura et al. | Suppression of thyroid lesions in rabbits by treatment with cyclophosphamide after the induction of thyroiditis | |
| WOLLHEIM | Immunoglobulin changes in the course of infectious mononucleosis | |
| Stedman et al. | Purification of Newcastle disease virus antibody from the egg yolk of the hen | |
| Wunderlich et al. | Characteristics of a cytotoxic human lymphocyte-dependent antibody |